Biomedical subjects
Publications and source records attributed to C J Briggs.
We report that interference with the cholesterol assay using the cholesterol oxidase: p-aminophenazone method which is observed during lipoprotein preparation, is caused by the anti-bacterial agent thimerosol used in the preparation. We suggest that an alternative anti-bacterial agent should be used in these circumstances.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Analysis of C57BL/6J in equilibrium A/J allophenic mice for their lymphocyte composition, using H-2 antigens as external markers, and glucose phosphate isomerase (GPI) isozymes as internal markers, has led to the discovery of two unusual mice. Both mice showed heterodimers of GPI isozymes upon electrophoresis of the lymphocyte lysate. Specific anti-H-2 antisera confirmed that the cells of the mice were of C57BL/6J and A/J origin, as expected, but that the "A/J" cells seemed to behave as F1 hybrids containing the Gpi-1a and Gpi-1b alleles. Possible origins of the Gpi-1b allele in the "A/J" cells are discussed.
The binding of drugs to plasma proteins has been studied extensively using a variety of methods, including equilibrium dialysis. Published information on controls used in these studies is frequently inadequate; in other cases, there are deficiencies in the experimental design for the controls. A method is described that eliminates many of the problems associated with artifactual errors in dialysis studies. Multiple replicated controls are performed at the same time as the test, under identical conditions. The controls are used to correct for concentration-dependent binding of drug to the membrane or other equipment. The method was used to determine the binding of sulfadimethoxine to CF-IV-1 alpha-globulin at therapeutic concentrations. The level of binding was low (9-13%), but the stringent control technique permitted statistical analysis which showed each mean test value to be significantly different from its corresponding control. Furthermore, there was a linear relationship between the control-corrected percentage binding values and total drug concentration, whereas there was no correlation between total drug concentration and the uncorrected percentage binding values.
Monoclonal antibodies (MAb) that detect specific lymphocyte subsets of man were tested for their reactivity with peripheral blood lymphocytes (PBL) and established cell lines of owl monkeys (Aotus trivirgatus) and marmosets (Saguinus spp). Results of these studies showed that certain determinants were conserved and that the pattern of reactivity observed in one genus (or even species) could not be used to predict the reactivity in another. On owl monkey PBL, reactivity equivalent to that on human PBL was observed with OKT11a, anti-Leu 3a, B1, and anti-HLA-DR MAb thus detecting T cell, helper/inducer T cell, B cell, and HLA-DR determinants. After neuraminidase treatment of owl monkey PBL, reactivity with anti-Leu 5 and OKT8 (T cell and suppressor/cytotoxic T cell determinants) was observed. Cell separation experiments indicated these determinants were found on lymphocytes with the same general properties as those of human origin. The use of these MAb to examine owl monkeys infected with Herpesvirus saimiri and tumor cell lines established from H. saimiri-inoculated monkeys revealed that the virus was found in OKT11a-positive, B1-negative cells. In chronically infected nondiseased animals, H. saimiri was found in anti-HLA-DR-negative cells and was restricted to anti-Leu 3a-positive cells (two animals) or was nearly equally distributed in anti-Leu 3a-positive and negative cells (one animal). Established H. saimiri tumor cell lines had the phenotype OKT11 a-positive, anti-HLA-DR-positive, B1-negative and were either anti-Leu 3a-positive or negative. Studies of interleukin 2-responsive tumor cells in short-term culture suggested the tumor was composed of virus-positive anti-Leu 3a-positive and negative populations.
Treatment of fresh sera with polyethylene glycol 6000 at a final concentration of 100 g/l produced selective precipitation of low-density lipoproteins with only traces of contamination with high-density lipoproteins, as determined by electroimmunoassay using antisera to human alpha1-lipoprotein and human beta-lipoprotein. Supernatants collected for high-density lipoprotein-cholesterol estimation were free from low-density lipoproteins. Precipitates sedimented readily from specimens with high triglyceride contents, and secondary precipitation during enzymatic cholesterol determinations was absent. Values obtained by this method correlated well with those obtained by precipitation of low-density lipoproteins with heparin and manganous ions at concentrations optimal for discrete of lipoprotein classes (r = 0.975; p less than 0.001).
Explore the source record for details and available documents.
Theophylline protein binding was 58-82% in serum from six normal adults and 42 asthmatic patients, 1-25 years old, who were given 5 mg of theophylline/kg. The binding range was greatest in young patients, but the proportion of protein-bound drug did not correlate with age. Theophylline protein binding was higher than previously reported. The effect of binding should be considered in patients who do not have optimal bronchodilation from theophylline despite total serum theophylline concentrations of 10-20 microgram/ml.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The pharmacokinetics of HI-6 were studied following intravenous administration to beagle dogs (n = 7). The bioavailability of two different strength intramuscularly administered doses was also determined in the same animals. After a 20 mg kg-1 intravenous dose, the mean (+/- S.D.) initial HI-6 plasma concentration was 93.1 +/- 10.8 micrograms ml-1. The mean half-life was 48.2 +/- 17.7 min, the mean total body clearance was 5.16 +/- 0.81 ml min-1 kg-1, the mean apparent volume of distribution was 0.37 +/- 0.20 l kg-1 and 61.2 +/- 14.6 per cent of the dose was excreted as unchanged drug. The pharmacokinetic constants calculated following the 20 mg kg-1 intramuscular doses of 250 and 25 mg ml-1 solutions were not significantly different from those obtained following the intravenous dose. Also, the areas under the plasma concentration versus time curves were not significantly different indicating 100 per cent bioavailability from the intramuscular route of administration.
The effect of fasting, atropine, and poisoning by an organophosphate anticholinesterase soman (pinacolyl methylphosphonofluoridate) on the pharmacokinetics of the acetylcholinesterase oxime reactivator HI-6 (CAS Reg. No. 34433-31-3; 1-[(4-(aminocarbonyl)pyridinio)methoxy)methyl)-2-(hydroxy imino)methyl) pyridinium dichloride) was investigated. Pharmacokinetic parameters (elimination half-life, volume of distribution, clearance rate) were determined for the following groups: (1) a 20 and 50 mg kg-1 dose of HI-6; (2) a 50 mg kg-1 dose of HI-6 after fasting for 18 h (water ad lib); (3) a 50 mg kg-1 dose of HI-6 at 0, 4, and 24 h after atropine (17.4 mg kg-1, i.p.) and soman (287 micrograms kg-1, s.c.); and (4) a 50 mg kg-1 dose of HI-6 at 0 and 4 h after soman (100 micrograms kg-1, s.c.). Fasting increased significantly (p less than 0.05) the elimination of half-life (t1/2) and tended to increase the volume of distribution (Vd) and decrease the clearance rate (CL). Following soman (287 micrograms kg-1) poisoning the t1/2 of HI-6 increased from 8.6 min to 21.6 min and the Vd increased to 0.731 kg-1. At the lower soman dose (100 micrograms kg-1) no significant effect on HI-6 pharmacokinetics was found. Atropine (17.4 mg kg-1: i.p.) pretreatment increased the t1/2 and CL while having no effect on the Vd. By 24 h the pharmacokinetic parameters of HI-6 in the various treatment groups were not significantly different from the control group. The changes in the pharmacokinetics of HI-6 following soman and atropine are probably the result of haemodynamic changes.